Andere Sprachen Karolinska Development AB

Aktien

A0M84G

SE0002190926

KDEV

Verzögert Nasdaq Stockholm Andere Börsenplätze 13:55:03 23.04.2024			% 5 Tage	% 1. Jan.
1,52 ^SEK	+0,93 %		+0,93 %	-10,48 %

16.04.	Karolinska Development AB (Publ) gibt bekannt, dass Bjorn Cochlovius die Wiederwahl abgelehnt hat	CI
16.02.	Karolinska Development AB (publ) meldet Ergebniszahlen für das vierte Quartal und das Gesamtjahr bis zum 31. Dezember 2023	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Notice of Annual General Meeting in Karolinska Development AB (publ)	16.04.
Karolinska Development AB Announces That Björn Cochlovius Has Declined Re-Election	16.04.
Karolinska Development : portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC	22.03.
Karolinska Development’s portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC	22.03.
Karolinska Development Annual Report 2023 published	22.03.
Karolinska Development Annual Report 2023 published	22.03.
Karolinska Development : portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million	14.03.
Karolinska Development’s portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million	14.03.
Karolinska Development : portfolio company Biosergen publishes prospectus due to rights issue of units	14.03.
Karolinska Development’s portfolio company Biosergen publishes prospectus due to rights issue of units	14.03.
Karolinska Development : portfolio company Umecrine Cognition presents preclinical Parkinson's data on golexanolone at AD/PD	06.03.
Karolinska Development’s portfolio company Umecrine Cognition presents preclinical Parkinson’s data on golexanolone at AD/PD	06.03.
Year-end Report - January-December 2023	16.02.
Karolinska Development AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	16.02.
Karolinska Development Portfolio Company AnaCardio Completes SEK150 Million Funding Round	17.01.
Karolinska Development’s portfolio company AnaCardio secures SEK 50 million as part of its Series A investment round	17.01.
AnaCardio AB announced that it has received SEK 150 million in funding from Industrifonden, Karolinska Development AB, Flerie Invest AB	17.01.
Karolinska Development's portfolio company OssDsign reports exceptional clinical data for its nanosynthetic bone graft product	09.01.
Karolinska Development's portfolio company OssDsign expects fourth-quarter revenues to exceed market estimates	06.12.
Karolinska Development’s portfolio company PharmNovo´s drug candidate PN6047 in a NIDA funded collaboration	04.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Karolinska Development AB

Aktien

A0M84G

SE0002190926

KDEV

Andere Sprachen

Filter